Tag: Cancer Drugs

Many patients who are diagnosed with cancer will require treatment with cancer drugs. Treatment with cancer drugs is usually led by a doctor known as a medical oncologist.

Heidelberg Pharma and Magenta Therapeutics prolongate a research cooperation

drug development
Heidelberg Pharma announced that its partner Magenta Therapeutics exercises its option to further continue the development of an Antibody Targeted Amanitin Conjugate.

Themis Bioscience signs licensing agreement with Max-Planck-Innovation

research
Themis announced that it has entered into a license agreement with Max-Planck-Innovation GmbH, the technology transfer agency of the Max Planck Society in Germany.

Bristol-Myers Squibb entered into a clinical trial collaboration with Compugen

lab-tubes
Bristol-Myers Squibb Company and Compugen announced the companies have entered into a clinical trial collaboration to evaluate the safety and tolerability of Compugen’s COM701.

MEI Pharma and BeiGene will jointly develop cancer drugs

laboratory test
MEI Pharma and BeiGene announced a clinical collaboration to evaluate the safety and efficacy of MEI's ME-401 in combination with BeiGene's zanubrutinib.

Pfizer rewards $3 million in grants for breast cancer researchers

lab research
Pfizer announced the recipients of the Advancing Science through Pfizer Investigator Research Exchange (ASPIRE) Breast Cancer Research Awards.

KSQ Therapeutics receives $80 million for cancer therapies development

investments
KSQ Therapeutics announced that the company has secured an $80 million financing to advance oncology drug candidates generated from the company’s proprietary CRISPRomics engine into clinical studies.

Abzena and Tmunity will develop new CAR-T therapies

cells
Abzena has signed an antibody humanisation agreement with Tmunity Therapeutics, a clinical stage T cell therapy company and a leader in the development of new CAR-T therapies.

Cuba and USA established the first joint biotech company

drug discovery
The Biotechnology and Pharmaceutical Industries Group Biocubafarma announced that the first Cuban-American biotechnology company has been created: Innovative Immunotherapy Alliance SA.

Sechenov University scientists took part in creation of cancer nanotechnology

research
Scientists of Sechenov University took part in creation of cancer nanotechnology enables targeted delivery of substantial payloads of drugs to cancer sites.

LineaRx will develop cancer vaccines aided by Italian biotech

gene
LineaRx, a subsidiary of Applied DNA Sciences, has entered into a Joint Development Agreement with Takis SRL and Evvivax SLR. They will focus on developing anti-cancer vaccines.

Takeda and Molecular Templates will jointly develop engineered toxin bodies

takeda
Molecular Templates and Takeda announced an agreement for the joint development of CD38-targeted engineered toxin bodies (ETBs) for the treatment of patients with diseases such as multiple myeloma.

Israeli drug discovery company receives $7.8 million funding from Bayer

drug-development
Compugen, an Israeli clinical-stage cancer immunotherapy and predictive target discovery company, has earned a $7.8 million milestone payment from German pharma giant Bayer.

Australian biotech to cooperate with the University of Jaén on drug discovery

lab-tests
Propanc Biopharma, an Australian clinical stage biopharmaceutical company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors (pancreatic, ovarian...

The world leading hub for cancer research was created in UK

cancer-test
London will be transformed into a leading hub for cancer biotherapeutics research and treatment, with a new investment from Cancer Research UK.

Researchers are testing new cancer vaccine against melanoma

tubes
An experimental cancer vaccine that boosts the immune system’s ability to fight cancers could work in tandem with other cancer therapies to fight aggressive tumors.

Citoxlab and Experimental Pharmacology and Oncology Berlin-Buch became partners

lab-tubes
Citoxlab (France) announced an investment and partnership deal with Experimental Pharmacology and Oncology Berlin-Buch GmbH (EPO).